Vol 48, No 1 (2017)
Prace oryginalne / Original research articles
Published online: 2017-01-01

open access

Page views 171
Article views/downloads 175
Get Citation

Connect on Social Media

Connect on Social Media

Role of HLA match on results of hematopoietic stem cell transplantations from unrelated donors in children with acute leukemia and bone marrow failure syndromes

Jan Styczyński1, Robert Dębski1, Anna Krenska1, Krzysztof Czyżewski1, Natalia Bartoszewicz1, Ewa Demidowicz1, Ninela Irga-Jaworska2, Elżbieta Drożyńska2, Marcin Płonowski3, Maryna Krawczuk-Rybak3, Tomasz Ociepa4, Tomasz Urasiński4, Mariusz Wysocki1
DOI: 10.1016/j.achaem.2017.01.002
Acta Haematol Pol 2017;48(1):48-53.



In case of the lack of matched family donors (MFD), hematopoietic stem cell transplantation (HSCT) from unrelated donor (UD) is an established procedure for many acquired and congenital disorders of the hematopoietic system, including malignancies and bone marrow failure (BMF) syndromes.


The analysis of the results of HSCT in patients with acute leukemia or BMF syndromes from UDs with respect to human leukocyte antigen (HLA) match.

Patients and methods

A total number of 97 of HSCT from UDs performed in single center between 2007 and 2015 in children and adolescents with acute lymphoblastic (ALL) or myeloblastic leukemia (AML) and BMF syndromes were included into this analysis. HLA match between donor and recipient was analyzed at the allele level and classified as 10/10, 9/10 or 8/10. Data were compared to results of 56 MFD-HSCTs. Probability of overall survival (pOS) was given for 3-year and 1-year (as required by JACIE standards) time periods.


The mean survival for all patients estimated by Kaplan–Meier method was 4.8 years (95%CI=4.1–5.5 years). The 3-year pOS after all UD-HSCT was 0,60±0,05, and with respect to 10/10, 9/10 and 8/10 HLA match: 0,61±0,06; 0,59±0,09 and 0,60±0,22, respectively (ns). In patients with AML, 3-year pOS reached 52%, 60% and 60%, respectively. In patients with ALL, 3-year pOS was 73% and 62% (ns) for 10/10 and 9/10 HLA match, respectively, while for BMF syndromes 86% and 57% (ns), respectively.


Current data suggest that results of mismatched and matched UD-HSCT in children with acute leukemia might be comparable.

Article available in PDF format

View PDF Download PDF file